Formed in 2019, The Amyloidosis Forum has been developed through a public-private partnership between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA). The overarching goal of the Forum is to optimize innovation and accelerate the advancement of new therapeutics by addressing scientific gaps and needs through the conduct of mutually beneficial scientific activities in the precompetitive domain that aid in the scientific evaluation of the efficacy and safety of new therapies.
2024 Amyloidosis Forum Annual Meeting
Wednesday, October 23, 2024
Watch Recordings
Participants including clinicians, researchers, FDA and global health authorities, industry partners, patients, and the Amyloidosis Research Consortium (ARC) walked through the process and plans of the Amyloidosis Forum working groups to outline goals and touchstones for future programs and research.